TABLE: Avalanche outperforms with the week's best IPO
This article was originally published in Scrip
Executive Summary
Gene therapy for eye diseases captured the interest of investors during the week ending 1 August with an initial public offering from Avalanche Biotechnologies that launched at the top of a preliminary price range and a first-day closing price that was 47% above the IPO value.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
